Skip to main content
Isomer
  1. Home
  2. Automated
  3. List of product information
  4. TIMOPTOL-XE OPHTHALMIC SOLUTION 0.5% [SIN08619P]

TIMOPTOL-XE OPHTHALMIC SOLUTION 0.5% [SIN08619P]

Active ingredients: TIMOPTOL-XE OPHTHALMIC SOLUTION 0.5%

Last updated 26 October 2025

Product Info

TIMOPTOL-XE OPHTHALMIC SOLUTION 0.5%

[SIN08619P]

Product information

Active Ingredient and Strength

TIMOLOL MALEATE EQV TIMOLOL - 5 MG/ML

Dosage Form

SOLUTION

Manufacturer and Country

SANTEN PHARMACEUTICAL CO., LTD. NOTO PLANT - JAPAN

Registration Number

SIN08619P

Licence Holder

SANTEN PHARMACEUTICAL ASIA PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

S01ED01

INDICATIONS
TIMOPTOL-XE is indicated for the reduction of elevated intraocular pressure in patients with:

  • ocular hypertension

  • chronic open-angle glaucoma

  • aphakia and glaucoma

  • secondary glaucoma (some cases)

  • narrow angles and a history of spontaneous or iatrogenically induced narrow-angle closure in the opposite eye in whom reduction of intraocular pressure is necessary (see PRECAUTIONS – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information)

DOSAGE AND ADMINISTRATION
The usual starting dose is one drop of 0.25% TIMOPTOL-XE in the affected eye(s) once a day. If the clinical response is not adequate, the dosage may be changed to one drop of 0.5% TIMOPTOL-XE in the affected eye(s) once a day. Invert the closed container and shake once before each use. It is not necessary to shake the container more than once.

If needed, concomitant therapy with other agent(s) for lowering intraocular pressure may be given with TIMOPTOL-XE. The use of two topical beta-adrenergic blocking agents is not recommended (See PRECAUTIONS – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Other topically applied medications should be administered no less than 10 minutes before TIMOPTOL-XE.

When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced. This may result in an increase in local activity.

HOW TO TRANSFER PATIENTS FROM OTHER THERAPY
When a patient is transferred from TIMOPTOL to TIMOPTOL-XE, TIMOPTOL should be discontinued after proper dosing on one day, and treatment with the same concentration of TIMOPTOL-XE started on the following day.

When a patient is transferred from another topical ophthalmic beta-adrenergic blocking agent, that agent should be discontinued after proper dosing on one day and treatment with TIMOPTOL-XE started on the following day with one drop of 0.25% TIMOPTOL-XE in the affected eye once a day. The dose may be increased to one drop of 0.5% TIMOPTOL-XE once a day if the clinical response is not adequate.

When a patient is transferred from a single antiglaucoma agent, other than a topical ophthalmic beta-adrenergic blocking agent, continue the agent and add one drop of 0.25% TIMOPTOL-XE to each affected eye once a day. On the following day, discontinue the previously used antiglaucoma agent and continue TIMOPTOL-XE. If a greater response is required, substitute one drop of 0.5% TIMOPTOL-XE for the 0.25% dosage.

CONTRAINDICATIONS
TIMOPTOL-XE is contraindicated in patients with:

  • Reactive airway disease, bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease

  • Sinus bradycardia; sick sinus syndrome; sino-atrial block; second or third degree atrioventricular block; overt cardiac failure; cardiogenic shock

  • Hypersensitivity to any component of this product